Overview

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.

Phase:

PHASE2

Details

Lead Sponsor:

Brii Biosciences Limited

Collaborator:

Vir Biotechnology, Inc.